{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:56:02Z","timestamp":1791510962616,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Rituximab has become a standard treatment for non\u2010Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) patients. This non\u2010interventional study aimed to evaluate the effectiveness and safety of subcutaneous (SC) rituximab in routine clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients with previously untreated CD20 positive DLBCL or FL who received rituximab SC and chemotherapy as first\u2010line treatment were observed between 07\/2014 and 07\/2019 at 99 institutions in Germany. Primary endpoint was the (unconfirmed) complete remission (CR\/CRu) rate. Primary outcome was analyzed inferentially; other variables were evaluated descriptively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall 583 patients (247 FL; 336 DLBCL) were evaluated. CR\/CRu rates were 51.4% (95% CI: 45.2; 57.6) in the FL set and 48.5% (95% CI: 43.2; 53.8) in the DLBCL set. Regarding progression\u2010free survival in the FL group, the probability of being event\u2010free was 94.2% in the first year and 86.2% in the second year. An overall response was achieved in 85.8% (FL) and 85.4% patients (DLBCL). Patient satisfaction at the end of study with the time saving simplification of the SC vs. intravenous route was 98% for FL and 97% for DLBCL. 45.3% of FL and 47.0% of DLBCL patients experienced an adverse event of grade \u22653. Serious adverse events of grade \u22653 occurred in 27.9% FL and 32.4% DLBCL patients, with the highest incidences for leucopenia, anemia, nausea, and fatigue. No new safety signals were detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results confirmed the effectiveness and safety of rituximab SC in both the FL and the DLBCL group. Satisfaction of patients and nurses with SC administration was high.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5160","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T09:31:08Z","timestamp":1661506268000},"page":"2739-2751","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non\u2010interventional study <scp>MabSCale<\/scp>"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7672-3905","authenticated-orcid":false,"given":"Jan","family":"D\u00fcrig","sequence":"first","affiliation":[{"name":"Department of Hematology University Medicine Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Oncological Practice  Naunhof Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Gerhardt","sequence":"additional","affiliation":[{"name":"Medical Care Centre for Blood and Cancer Diseases  Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ritter","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Hospital Sindelfingen\u2010B\u00f6blingen  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Hapke","sequence":"additional","affiliation":[{"name":"Marienkrankenhaus Hamburg  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"He\u00dfling","sequence":"additional","affiliation":[{"name":"Onkologie am Segelfliegerdamm  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staib","sequence":"additional","affiliation":[{"name":"St.\u2010Antonius Hospital  Eschweiler Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieder","family":"Wolff","sequence":"additional","affiliation":[{"name":"Roche Pharma AG, Biometrics &amp; Epidemiology  Grenzach\u2010Wyhlen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Krumm","sequence":"additional","affiliation":[{"name":"Roche Pharma AG, Department of Hematology  Grenzach\u2010Wyhlen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig Fischer","family":"von Weikersthal","sequence":"additional","affiliation":[{"name":"St. Marien Health Centre  Amberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization corp\u2010author.Diffuse large B\u2010cell lymphoma Union for International Cancer Control. Accessed December 15 2021. Available from:http:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/applications\/DiffuseLargeBCellLymphoma.pdf"},{"key":"e_1_2_11_3_1","unstructured":"Lymphoma Research foundation.Diffuse large B\u2010cell lymphoma. Accessed December 15 2021. Available from:https:\/\/lymphoma.org\/aboutlymphoma\/nhl\/dlbcl\/"},{"key":"e_1_2_11_4_1","unstructured":"LenzG ChapuyB Gla\u00df B et al.Diffuses gro\u00dfzelliges B\u2010Zell\u2010Lymphom Onkopedia Leitlinie [German]. Accessed December 15 2021. Available from:https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/diffuses\u2010grosszelliges\u2010b\u2010zell\u2010lymphom\/@@guideline\/html\/index.html"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70078-0"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.173583"},{"key":"e_1_2_11_9_1","unstructured":"Pinter\u2010BrownLC JeyakumarD.Follicular lymphoma management overview. Accessed December 15 2021. Available from:https:\/\/emedicine.medscape.com\/article\/203268\u2010overview"},{"key":"e_1_2_11_10_1","unstructured":"BuskeC DreylingM HeroldM et al.Follikul\u00e4res Lymphom Onkopedia Leitlinie [German]. Accessed December 15 2021. Available from:https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/follikulaeres\u2010lymphom\/@@guideline\/html\/index.html#ID0ELB"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363080-00005"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11201110-000000000-00000"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg175"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2631"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"},{"key":"e_1_2_11_21_1","unstructured":"MabTheraEUSummary of Product Characteristics. Roche Registration Limitedhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000165\/WC500025821.pdf"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_2_11_24_1","first-page":"1","volume-title":"Atlas of Clinical Hematology","author":"Cheson BD","year":"2008"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0610-z"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.013"},{"key":"e_1_2_11_31_1","article-title":"Rituximab with involved filed irradiation for early\u2010stage nodal follicular lymphoma: results of the MIR study","volume":"2","author":"Herfarth K","year":"2018","journal-title":"Hema"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28659"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1549"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:18:38Z","timestamp":1732522718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cam4.5160"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5160","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"2022-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}